ANVS - Annovis Bio, Inc. Stock Analysis | Stock Taper

SCREENER COMPARE ANY 2 STOCKS

ANVS

ANNOVIS BIO, INC.

NYSE

$1.72

▼ DOWN 4.97% (-0.09)

KEY STATISTICS

Market Cap$73.17 M

52w High$5.50

52w Low$1.54

Dividend Yield—

Frequency—

P/E-1.01

Volume498.12K

Shares Out.42.54M

COMPANY

LEADERSHIP

Maria L. Maccecchini

CHIEF EXECUTIVE

Maria L. Maccecchini

COMPENSATION 2026

Salary$808,000

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$0

Total$808,000

ABOUT

SECTOR

Healthcare

WENT PUBLIC

January 29, 2020

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

7

PRICE TARGET

Target High$30.00

Target Low$21.00

Target Median$26.00

Target Consensus$25.67

UPCOMING EARNINGS

DateNov 11, 2026

DayWednesday

Rev. Est.—

NOV

11

WED

PRICE

$1.72 ▼ DOWN 4.97% (−$0.09)

About Annovis Bio, Inc.

https://www.annovisbio.com ↗

Annovis Bio, Inc. is a clinical-stage company developing drugs like Buntanetap for neurodegenerative diseases, including Alzheimer's and Parkinson's, with ongoing trials for TBI, stroke, and cognitive enhancement.

INDUSTRY

Biotechnology

A PRODUCT ANNOVIS BIO, INC. IS KNOWN FOR

Buntanetap

Buntanetap

An experimental oral drug in Phase 3 trials targeting Alzheimer's and Parkinson's by inhibiting neurotoxic protein formation to slow or halt neurodegeneration.

COMPETITORS

COMPETITOR

ETFS HOLDING THIS STOCK

ETFS HOLDING

12

LISTED HERE

2

RANKED BY POSITION SIZE

0.01% · 104.7K

INSTITUTIONAL OWNERSHIP

SHARES OWNED

22.68%

HOLDERS

86

TOP 12 OF 86 · RANKED BY POSITION SIZE

Empery Asset Management, LP

2.4M sh · $4.47M

Marshall Wace, Llp

1.8M sh · $3.43M

Tudor Investment Corp Et Al

1.4M sh · $2.52M

Renaissance Technologies LLC

1.0M sh · $1.86M

Vanguard Group Inc

923.2K sh · $3.19M

Two Sigma Investments, LP

627.7K sh · $1.4M

Susquehanna International Group, Llp

303.3K sh · $1.05M

Geode Capital Management, LLC

283.8K sh · $528.13K

Jane Street Group, LLC

251.2K sh · $869K

Blackrock, Inc.

249.9K sh · $464.73K

Citadel Advisors LLC

243.7K sh · $453.25K

D.A. Davidson & Co.

160.8K sh · $556.29K

RATINGS SNAPSHOT

Overall rating: C+

Discounted Cash Flow4

Return On Equity5

Return On Assets1

Debt To Equity1

Price To Earnings1

Price To Book1

Overall Score2

INSIDER TRADES

★

DIRECTOR

Hoffman Michael B

Purchase · 54.9K shares

2026-05-20

★

DIRECTOR

Hoffman Michael B

Purchase · 18.8K shares

2026-05-20

★

DIRECTOR

Hoffman Michael B

Purchase · 2.6K shares

2026-05-20

★

DIRECTOR

Hoffman Michael B

Purchase · 713.8K shares

2026-04-02

MOST RECENT ANALYST GRADES

GRADE SUMMARY

BUY 2

2 GRADES IN THE LAST 12 MONTHS

Canaccord Genuity BUY

HC Wainwright & Co. BUY

SECTORS PEERS

PEER	PRICE
PYPD	$5.07	COMPARE
CELU	$1.58	COMPARE
ELUT	$0.88	COMPARE
EVAX	$3.01	COMPARE
PDSB	$0.21	COMPARE
RVPH	$0.52	COMPARE
BTAI	$0.18	COMPARE
BCAB	$1.74	COMPARE